Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab.

Cancers (Basel) · 2025 · PMC12523717 · PMID 41097685

Europe PMC DOI

hedged sentences

0.0930

closest p · 1.9× alpha

0.0930

boldest claim

The sentences

did not reach statistical significancep = 0.093so close (0.05 < p ≤ 0.1)

16.2 months without steroids), but this did not reach statistical significance given the small sample size (log-rank p = 0.093; Supplementary Figure S4C ).

also in 111,027 other papers

marginal significanceno p-value reported

Importantly, the association between ICI treatment duration and OS and PFS only showed marginal significance in the univariate analysis.

also in 5,069 other papers

marginally significantno p-value reported

We further stratified patients who received LRT and found that the survival advantage associated with grade 2 irLI was present in patients with and without LRT ( Supplementary Figure S5A,C ), and the difference was statistically significant in PFS for those with LRT ( Supplementary Figure S5B ) and marginally significant for those without LRT ( Supplementary Figure S5D ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.